128 related articles for article (PubMed ID: 38810147)
21. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
J Virol Methods; 2015 Sep; 222():28-33. PubMed ID: 25997377
[TBL] [Abstract][Full Text] [Related]
22. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
23. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
24. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.
Ngo D; Sinha S; Shen D; Kuhn EW; Keyes MJ; Shi X; Benson MD; O'Sullivan JF; Keshishian H; Farrell LA; Fifer MA; Vasan RS; Sabatine MS; Larson MG; Carr SA; Wang TJ; Gerszten RE
Circulation; 2016 Jul; 134(4):270-85. PubMed ID: 27444932
[TBL] [Abstract][Full Text] [Related]
25. Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma.
Graumann J; Finkernagel F; Reinartz S; Stief T; Brödje D; Renz H; Jansen JM; Wagner U; Worzfeld T; Pogge von Strandmann E; Müller R
Front Oncol; 2019; 9():1150. PubMed ID: 31737572
[TBL] [Abstract][Full Text] [Related]
26. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
[TBL] [Abstract][Full Text] [Related]
27. Comparison of proteomic methods in evaluating biomarker-AKI associations in cardiac surgery patients.
Liu RX; Thiessen-Philbrook HR; Vasan RS; Coresh J; Ganz P; Bonventre JV; Kimmel PL; Parikh CR
Transl Res; 2021 Dec; 238():49-62. PubMed ID: 34343625
[TBL] [Abstract][Full Text] [Related]
28. Carcinogenesis of β-Propiolactone: A Computational Study.
Španinger E; Bren U
Chem Res Toxicol; 2020 Mar; 33(3):769-781. PubMed ID: 32056425
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of induction of DNA damage and lacZ gene mutations in stomach mucosa of mice treated with beta-propiolactone and N-methyl-N'-nitro-N-nitrosoguanidine, using single-cell gel electrophoresis and MutaMouse models.
Brault D; Renault D; Tombolan F; Thybaud V
Environ Mol Mutagen; 1999; 34(2-3):182-9. PubMed ID: 10529742
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of poliovirus with beta-propiolactone.
Jiang SD; Pye D; Cox JC
J Biol Stand; 1986 Apr; 14(2):103-9. PubMed ID: 3020055
[TBL] [Abstract][Full Text] [Related]
31. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
Jacob J; Ngo D; Finkel N; Pitts R; Gleim S; Benson MD; Keyes MJ; Farrell LA; Morgan T; Jennings LL; Gerszten RE
Circulation; 2018 Mar; 137(12):1270-1277. PubMed ID: 29222138
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of African horse-sickness virus by betapropiolactone and by pH.
Parker J
Arch Virol; 1975; 47(4):357-65. PubMed ID: 237497
[TBL] [Abstract][Full Text] [Related]
33. Effect of beta propiolactone on specific antibody measurements by ELISA.
Agbarakwe AE; Misbah SA; Griffiths H; Chapel HM
J Clin Pathol; 1993 Apr; 46(4):368-9. PubMed ID: 8496395
[TBL] [Abstract][Full Text] [Related]
34. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
[TBL] [Abstract][Full Text] [Related]
35. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Smith JG; Gerszten RE
Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
[TBL] [Abstract][Full Text] [Related]
36. Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine.
Zhao F; Liu L; Xu M; Shu X; Zheng L; Wei Z
Virol J; 2020 Oct; 17(1):163. PubMed ID: 33097081
[TBL] [Abstract][Full Text] [Related]
37. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells.
Billing AM; Ben Hamidane H; Bhagwat AM; Cotton RJ; Dib SS; Kumar P; Hayat S; Goswami N; Suhre K; Rafii A; Graumann J
J Proteomics; 2017 Jan; 150():86-97. PubMed ID: 27613379
[TBL] [Abstract][Full Text] [Related]
38. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems.
Qi An W; Guo Su Z; Wen Pan R; Ping Yang B; Chao Zhang Y; Shi L; Li Q
Hum Vaccin Immunother; 2014; 10(3):628-39. PubMed ID: 24401488
[TBL] [Abstract][Full Text] [Related]
39. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine.
Race E; Stein CA; Wigg MD; Baksh A; Addawe M; Frezza P; Oxford JS
Vaccine; 1995 Nov; 13(16):1567-75. PubMed ID: 8578844
[TBL] [Abstract][Full Text] [Related]
40. In vitro acylation of the xi-amino group of L-lysine in calf thymus histones by the carcinogen, beta-propiolactone.
Segal A; Garte SJ
Chem Biol Interact; 1976 Dec; 15(4):319-26. PubMed ID: 1009630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
